1 / 27

Lung Cancer in 2011

Lung Cancer in 2011. Dr. Natasha Leighl, MD MMSc FRCPC Medical Oncologist, Princess Margaret Hospital Assistant Professor, Medicine, University of Toronto. Lung Cancer: a growing problem. One of the most common cancers in Canadians, and the leading cause of cancer deaths (27%)

maia
Télécharger la présentation

Lung Cancer in 2011

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lung Cancer in 2011 Dr. Natasha Leighl, MD MMSc FRCPC Medical Oncologist, Princess Margaret Hospital Assistant Professor, Medicine, University of Toronto

  2. Lung Cancer: a growing problem One of the most common cancers in Canadians, and the leading cause of cancer deaths (27%) 1.4 million new cases per year, 1.2 million deaths Most present with advanced disease, severe symptoms North American incidence falling in men, rising in women Peak incidence in 70s Most ex-smokers, about 30% smokers, 15% nonsmokers

  3. Estimated new cases in Canada, 2011 25,500 22,200 23,600 25,300 Canadian Cancer Statistics 2011

  4. Estimated cancer deaths, Canada 2011 5 yr OS 4,100 95% 8,900 61% 5,100 87% 20,600 18% Canadian Cancer Statistics 2011

  5. Cancer Research Dollars

  6. Research Funding 7% of Canadian research dollars go to lung cancer, less than 1% of donations Breast cancer support, services outnumber lung cancer by more than 10 to 1 Approximately $23,000 research dollars spent per breast cancer patient, compared to $1,800 per lung cancer patient

  7. Causes of Lung Cancer • SMOKING!!!! (87%) • Occupational exposure • Asbestos, arsenic, nickel, petroleum • Radon, Radiation • Passive smoking • Age • ? Genetic predisposition • ?Environmental exposures-air pollution

  8. Lung Cancer Types Bronchial Pluripotential Stem Cell 15% Small Cell 85% Non-small Cell (NSCLC)

  9. 1972-1978 1963-1988 NCI 1962-1968 Histological Types of Lung Cancer Adenocarcinoma 75 Squamous cell 50 BAC Percent Large cell 25 Other 0 Gazdar and Linnoila, Seminars Oncol 1988; 15(3): 215

  10. T stage T1 -  3 cm, not in main bronchus

  11. T stage T1 -  3 cm, not in main bronchus T2 - >3 (<7)cm,2cm from carina, inv’n visceral pleura, subtotal atelectasis

  12. T stage T1 -  3 cm, not in main bronchus T2 - >3 (<7)cm,2 cm from carina, inv’n visceral pleura, subtotal atelectasis T3 – >7 cm, invade chest wall, diaphragm, med pleura, parietal pericard, total atelect, satellite nodules same lobe

  13. T stage T1 -  3 cm, not in main bronchus T2 - >3 (<7)cm,2 cm from carina, invn visceral pleura, subtotal atelectasis T3 – >7cm, invade chest wall, diaphragm, med pleura, parietal pericard, total atelect, satellite nod same lobe T4 – inv med, hrt, grtvessels, trachea, esoph, vert body, carina, nodules ipsilat lung, malignant pl effusion

  14. N stage N1 – ipsilateral peribronchial, pulmonary nodes

  15. N stage N1 – ipsilateral peribronchial, pulmonary nodes N2 – ipsilateral mediastinal, subcarinal nodes

  16. N stage N1 – ipsilateral peribronchial, pulmonary nodes N2 – ipsilateral mediastinal, subcarinal nodes N3 – contralateral med, hilar, any scalene, supraclav nodes

  17. M Stage M1a – nodule in contralateral lung, malignant effusion M1b – distant mets Common Sites: Liver Bone Brain Adrenals Pleura, Pericardium, Other Lung

  18. Survival by Pathologic Stage

  19. Changes to Staging - 2009 Current system implemented in 2009 Key changes from 1996 system: Tumors more than 7 cm moving from T2 to T3 Changing classification of same lobe satellite nodules from T4 to T3 Changing ipsilateral lung but different lobe metastases from M1 to T4, and contralateral lung nodules from M1 to “M1a” Changing malignant effusions from T4 to M1a

  20. Old Clinical Stage Current Clinical Stage

  21. Old Pathologic stage Current Pathologic Stage

  22. What tests do you need? • Diagnosis • Bronchoscopy (>90%) / mediastinoscopy (node), endobronchial ultrasound (with nodal biopsy, EBUS) • Needle aspirate or biopsy (>95%), sputum x 3(80% v 20%) • Video-Assisted Thoracoscopic Surgery (VATS) • Thoracentesis (pleural effusion) • Staging • Chest X-ray / CT Scan (Chest + Upper Abdomen) • Mediastinoscopy (assess node involvement), EBUS • Blood counts, chemistry • Bone scan (if indicated) • CT / MRI brain (if indicated) • FDG PET for SPN, resectable, Stage III NSCLC in Ontario

  23. PET for NSCLC PET image courtesy of Dr Nevin Murray, BC Cancer Agency

  24. PET in NSCLC • Solitary Pulmonary Nodules • FNA or biopsy best approach • Meta-analyses (no RCTs): • Sensitivity 96-97%, Specificity 78-86% • False negatives in low grade tumours (e.g. BAC, GGOs) • False positives in inflammatory conditions • So if biopsy not possible, PET uptake + - intervene. If negative, follow (CT q3m x 2 y)

  25. PET in NSCLC • Staging of Primary Lung Cancer • 11 systematic reviews, 3 RCTs, 22 other studies • Standard staging +/- PET • 51% relative reduction in futile thoracotomies in one trial; no difference in 2nd trial • PET vs. Standard Staging • Shorter time to diagnosis (14 days vs. 23) • Fewer mediastinoscopies, invasive tests to stage med • Indicated in addition to standard staging for resectable and stage 3 NSCLC • In early stage patients upstaged by PET (up to 15%), should verify results to confirm true positive

  26. PET in SCLC • Limited evidence in SCLC • PET accuracy in staging 83-99% (limited versus extensive stage disease) • Better to map out primary tumour and involved nodes, less sensitive for metastatic disease • May be helpful tool in radiation planning

More Related